NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
RedHill Biopharma Ltd (NASDAQ: RDHL)
RDHL Technical Analysis
2
As on 9th Jun 2023 RDHL STOCK Price closed @ 1.84 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.41 & Strong Sell for SHORT-TERM with Stoploss of 2.39 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RDHLSTOCK Price
Open | 1.94 | Change | Price | % |
High | 1.95 | 1 Day | -0.09 | -4.66 |
Low | 1.78 | 1 Week | -0.48 | -20.69 |
Close | 1.84 | 1 Month | -0.44 | -19.30 |
Volume | 75000 | 1 Year | -0.68 | -26.98 |
52 Week High 4.87 | 52 Week Low 0.14 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
RDHL Daily Charts |
RDHL Intraday Charts |
Whats New @ Bazaartrend |
RDHL Free Analysis |
|
RDHL Important Levels Intraday
RESISTANCE | 2.17 |
RESISTANCE | 2.06 |
RESISTANCE | 2.00 |
RESISTANCE | 1.93 |
SUPPORT | 1.75 |
SUPPORT | 1.68 |
SUPPORT | 1.62 |
SUPPORT | 1.51 |
RDHL Forecast May 2024
4th UP Forecast | 3.25 |
3rd UP Forecast | 2.8 |
2nd UP Forecast | 2.52 |
1st UP Forecast | 2.24 |
1st DOWN Forecast | 1.44 |
2nd DOWN Forecast | 1.16 |
3rd DOWN Forecast | 0.88 |
4th DOWN Forecast | 0.43 |
RDHL Weekly Forecast
4th UP Forecast | 3.02 |
3rd UP Forecast | 2.64 |
2nd UP Forecast | 2.41 |
1st UP Forecast | 2.17 |
1st DOWN Forecast | 1.51 |
2nd DOWN Forecast | 1.27 |
3rd DOWN Forecast | 1.04 |
4th DOWN Forecast | 0.66 |
RDHL Forecast2024
4th UP Forecast | 12.57 |
3rd UP Forecast | 9.13 |
2nd UP Forecast | 7 |
1st UP Forecast | 4.88 |
1st DOWN Forecast | -1.2 |
2nd DOWN Forecast | -3.32 |
3rd DOWN Forecast | -5.45 |
4th DOWN Forecast | -8.89 |
RedHill Biopharma Ltd ( NASDAQ USA Symbol : RDHL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RDHL Other Details
Segment | EQ | |
Market Capital | 252288000.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
RDHL Address
RDHL Latest News
RDHL Business Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Address: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service